Eli Lilly Hit $1 Trillion: What GLP-1 Revenue Means for Patients

In November 2025, Eli Lilly became the first healthcare company in history to reach a $1 trillion market capitalization. The engine behind that milestone: Mounjaro and Zepbound — two drugs containing the same compound, tirzepatide — generated $36.5 billion in combined sales for full-year 2025, roughly 56% of the company's total revenue. Those are not pharmaceutical numbers. Those are tech-company numbers.

The Numbers Behind the Milestone

Eli Lilly's full-year 2025 revenue hit $65.2 billion, up 45% from 2024. Earnings per share grew 86% to $24.21. Mounjaro (diabetes indication) contributed approximately $23 billion; Zepbound (obesity indication) added $13.5 billion. Revenue growth in Q4 alone was 43% year-over-year, beating analyst consensus by $1.3 billion.

For 2026, Lilly guided revenue of $80–83 billion, representing another 25% growth at the midpoint. Earnings per share are projected at $33.50–$35.00, a 40%+ increase. Goldman Sachs projects the US obesity drug market alone will reach $100 billion by 2030.

To put Lilly's scale in context: ten years ago, the company was described by one industry executive as a "backwater pharma" in Indianapolis. Its stock has climbed more than 37% in 2025 alone. The gap between Lilly and its chief GLP-1 rival, Novo Nordisk, has become a chasm — Novo's market cap sits under $200 billion, having lost roughly $400 billion in value since its mid-2024 peak.

Where the Money Is Going

The trillion-dollar question — literally — is what Lilly does with the revenue. For patients, two investment categories matter most:

Manufacturing expansion. Lilly has committed $27 billion to new US manufacturing facilities. At least three of the four new plants are dedicated to weight loss therapies, including production capacity for orforglipron, the company's oral GLP-1 candidate currently under FDA review. More manufacturing capacity means more supply, which means fewer shortages and — eventually — pricing pressure.

Pipeline development. Lilly has been on an acquisition spree: $1.3 billion for Verve Therapeutics (gene therapies for heart disease), $2.5 billion for Scorpion Therapeutics (oncology), and a deal for Adverum Biotechnologies (ophthalmology). Within the GLP-1 space specifically, Lilly is advancing retatrutide (a triple-agonist that achieved 28.7% weight loss in Phase 2), orforglipron (oral GLP-1), and additional indications for tirzepatide including MASH, sleep apnea, and heart failure.

The Competitive Divergence with Novo Nordisk

The Lilly vs. Novo story is increasingly one-directional. While Novo was first to market with GLP-1s through Ozempic and Wegovy, several factors have shifted momentum:

SURMOUNT-5 confirmed tirzepatide's clinical superiority over semaglutide for weight loss (20.2% vs. 13.7%). Novo has struggled to convince investors that Wegovy can maintain brand strength against a demonstrably more effective competitor.

Novo did gain the first-to-market advantage with oral semaglutide for obesity (approved December 2025, launched January 2026). But Lilly's oral candidate orforglipron is expected to reach the market in 2026 as well, potentially closing that gap quickly.

The market has priced in this divergence. Novo's stock dropped 45% in 2025 while Lilly's rose 37%.

What $1 Trillion Means for Drug Pricing

A trillion-dollar valuation built on two drugs creates both opportunity and scrutiny. On one hand, Lilly's LillyDirect program at $399/month represents the most aggressive brand-name pricing move in the GLP-1 space. At roughly 70% below Wegovy's list price, it shows that the manufacturer can choose to compete on price when strategically motivated.

On the other hand, Zepbound's list price remains over $1,000/month through traditional pharmacy channels, and millions of patients still lack insurance coverage. The Medicare GLP-1 Bridge program launching July 1, 2026 will offer $50/month copays — but only for specific products and only for Part D beneficiaries who meet eligibility criteria.

The core tension is this: GLP-1 medications are arguably the most impactful drug class in a generation, with proven benefits for weight loss, cardiovascular disease, kidney disease, and heart failure. But the economics of a $100 billion projected market mean that access remains deeply unequal. The same drugs that made one company worth $1 trillion remain unaffordable for a significant portion of the population that could benefit from them.

What This Means for Patients Right Now

For patients, Lilly's financial dominance translates into practical considerations:

Supply is stabilizing. After years of shortages, Lilly confirmed at J.P. Morgan in January 2026 that manufacturing bottlenecks are resolved. This is the direct result of the capital investment funded by GLP-1 revenue.

More options are coming. Orforglipron (oral tirzepatide) and retatrutide are both in late-stage development. The competitive pressure from these products — plus Novo's oral semaglutide — will likely push prices down over time.

The compounding window is closing. The FDA's April 30 proposal to exclude GLP-1s from the 503B bulks list would end the regulatory pathway that allowed compounded semaglutide and tirzepatide to fill the supply gap. Compounded versions ran $200–$400/month; without them, the gap between brand-name pricing and patient affordability widens — at least until competition and coverage expansion close it.

The trillion-dollar milestone is a leading indicator. It tells you where the pharmaceutical industry's resources, innovation, and competitive energy are flowing for the next decade. For better or worse, the GLP-1 era isn't slowing down — it's accelerating.

Sources

• Eli Lilly 8-K filing, Q4 2025 earnings and 2026 guidance, February 4, 2026. SEC filing.
• CNBC, "Eli Lilly hits $1 trillion market value, a first in health care," November 21, 2025.
• BioPharma Dive, "Eli Lilly becomes first drugmaker to hit $1 trillion in market value," November 21, 2025.
• Pharmaceutical Technology, "Eli Lilly soars past expectations to hit 45% sales growth in 2025," February 4, 2026.
• Goldman Sachs research estimate: US obesity market to reach $100 billion by 2030.